3-amino-4-(methylamino)benzamide | 39033-67-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-4-(methylamino)benzamide
• CAS: 39033-67-5
• 化学式: C₈H₁₁N₃O
• 分子量: 165.195
• InChiKey: MWUPFYDPRKUXOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-amino-4-(methylamino)benzamide 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS
  [FR] AMIDES HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DE PROTÉINE

  摘要：

  揭示了具有以下式（I）的化合物，其中Ra、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义，或其盐，特别是药用可接受的盐。

  公开号：

  WO2017175156A1
• 作为产物：
  描述：

  3-硝基-4-甲胺基-苯甲酰氯 在 palladium on activated charcoal 氨 、 氢气 作用下， 以 乙醇 为溶剂， 生成 3-amino-4-(methylamino)benzamide
  参考文献：
  名称：

  Novel non-benzimidazole chk2 kinase inhibitors

  摘要：

  In a recent paper, [Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K. M.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Chermagiri, R. P.; Karlsson, L.; Brietenbucher, J. G. J. Med. Chem. 2005, 48, 1873], we described the discovery of a class of benzimidazole chk2 kinase inhibitors, exemplified by compound 1, which had radio-protective effects in human T-cells subjected to ionizing radiation. Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.096

文献信息

• Methods for Chk2 inhibitor patient selection
  申请人：Altieri Dario

  公开号：US20080125358A1

  公开（公告）日：2008-05-29

  The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.

  本发明考虑了一种用于识别患有肿瘤或患有肿瘤风险、对激活的Chk2蛋白的各种抑制剂具有响应的受试者的方法。这些Chk2抑制剂可能包括苯并咪唑核结构及其衍生物。其他Chk2抑制剂可能包括核酸，例如特异于Chk2表达的沉默干扰RNA。其他Chk2抑制剂可能包括蛋白质，例如抗体。例如，本发明考虑了当在电离辐射期间或之后给予Chk2抑制剂时，肿瘤细胞凋亡增加。
• Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
  申请人：MAILLIET Patrick

  公开号：US20080153837A1

  公开（公告）日：2008-06-26

  This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

  这项发明涉及4-(苯并咪唑-2-基)芴和4-(氮杂苯并咪唑-2-基)芴的衍生物，涉及包含这些衍生物的药物组合物，以及涉及治疗与Hsp90蛋白活性相关的疾病的方法，包括给予这些衍生物。
• Process for the preparation of 4-(benzimidazolymethylamino) benzamidines
  申请人：Zerban Georg

  公开号：US20060004064A1

  公开（公告）日：2006-01-05

  A process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)benzamidine, the process comprising: (a) condensing an optionally suitably substituted diaminobenzene with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)phenylamino]acetic acid; (b) hydrogenating the product obtained from step (a); and (c) optionally carboxylating the amidino group of the product obtained from step (b).

  一种制备可选取代的4-苯并咪唑-2-基甲氨基苯胺的方法，该方法包括：（a）将可选适当取代的二氨基苯与2-[4-(1,2,4-噁唑-5-酮-3-基)苯基氨基]乙酸缩合；（b）加氢步骤（a）得到的产物；以及（c）可选地对步骤（b）得到的产物进行酰胺基羧化。
• Process for the Preparation of 4-(Benzimidazolylmethylamino)-Benzamides and the Salts Thereof
  申请人：Zerban Georg

  公开号：US20070185333A1

  公开（公告）日：2007-08-09

  The invention relates to a process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterised in that (a) an optionally correspondingly substituted diaminobenzene is condensed with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, (b) i) the product thus obtained is hydrogenated and ii) optionally the amidino group is carbonylated, without isolating the intermediate product of the hydrogenation beforehand; as well as a process for preparing a salt of an optionally substituted 4-(benzimidazol-2-ylmethylamino)-benzamidine, wherein (a) an optionally correspondingly substituted diaminobenzene is condensed with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, (b) the product thus obtained is hydrogenated, and (c) i) optionally the amidino group is carbonylated and ii) without prior isolation of the intermediate product of the carbonylation the desired salt is isolated.

  本发明涉及一种制备可选取代的4-苯并咪唑-2-基甲基氨基苯甲酰胺的过程，其特征在于：(a)将可选取代的二氨基苯与2-[4-(1,2,4-噁二唑-5-酮-3-基)-苯基氨基]-乙酸缩合；(b)将所得产物氢化，ii) 选择性地羰基化酰胺基团，而不预先分离氢化中间体产物；以及一种制备可选取代的4-(苯并咪唑-2-基甲基氨基)-苯甲酰胺盐的过程，其中(a)将可选取代的二氨基苯与2-[4-(1,2,4-噁二唑-5-酮-3-基)-苯基氨基]-乙酸缩合；(b)将所得产物氢化；(c)选择性地羰基化酰胺基团，ii) 在不预先分离羰基化中间体产物的情况下，分离所需的盐。
• PROCESS FOR THE PREPARATION OF 4-(BENZIMIDAZOLYLMETHYLAMINO)-BENZAMIDES AND THE SALTS THEREOF
  申请人：ZERBAN Georg

  公开号：US20100210845A1

  公开（公告）日：2010-08-19

  The invention relates to a process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterised in that (a) an optionally correspondingly substituted diaminobenzene is condensed with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, (b) i) the product thus obtained is hydrogenated and ii) optionally the amidino group is carbonylated, without isolating the intermediate product of the hydrogenation beforehand; as well as a process for preparing a salt of an optionally substituted 4-(benzimidazol-2-ylmethylamino)-benzamidine, wherein (a) an optionally correspondingly substituted diaminobenzene is condensed with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid, (b) the product thus obtained is hydrogenated, and (c) i) optionally the amidino group is carbonylated and ii) without prior isolation of the intermediate product of the carbonylation the desired salt is isolated.

  本发明涉及一种制备可选取代的4-苯并咪唑-2-基甲基氨基苯甲酰胺的过程，其特征在于：(a)将可选的相应取代的二氨基苯与2-[4-(1,2,4-噁唑啉-5-酮-3-基)-苯氨基]-乙酸缩合，(b)将所得产物氢化，ii)可选地，在未先分离氢化中间体产物的情况下，对氨基甲酰基进行羰基化；以及制备可选取代的4-(苯并咪唑-2-基甲基氨基)-苯甲酰胺盐的过程，其中(a)将可选的相应取代的二氨基苯与2-[4-(1,2,4-噁唑啉-5-酮-3-基)-苯氨基]-乙酸缩合，(b)将所得产物氢化，(c)可选地，对氨基甲酰基进行羰基化，ii)在未先分离羰基化中间体产物的情况下，分离所需的盐。